Logo image
Advancing the Science on Adenocarcinoma of the Cervix
Journal article   Peer reviewed

Advancing the Science on Adenocarcinoma of the Cervix

Amy E. McKeever, Sherry Burrell, Joan Rosen Bloch, Beth Chiatti, Maureen Gonzales, Jane Donovan and Yosefa Biratti
Journal for nurse practitioners, v 19(6), 104590
Jun 2023

Abstract

Adenocarcinoma Human papillomavirus Squamous Cell Carcinoma Cervical Cancer
Adenocarcinoma of the cervix (AC) is rising in women in the third decade of life. Compared with squamous cell cancer, widespread cervical cancer screening programs have failed to eradicate or decrease AC. AC, like squamous cell cancer, can be found in association alone or with cervical intraepithelial neoplasia. High-risk human papillomavirus DNA infection can be a risk factor for adenocarcinoma in situ and AC. Early stage AC is best treated surgically with cold knife conization or simple hysterectomy. Later-stage disease requires adjuvant treatment with chemotherapy and/or radiation. The prognosis varies based on stage and margin status. Improved education and awareness is needed to understand of the unique symptoms and diagnostic challenges of AC. •Adenocarcinoma of the cervix comprises 20% to 25% of all cervix cancers.•Adenocarcinoma of the cervix is increasing in women, particularly in women under 35 years old.•Adenocarcinoma of the cervix was first discussed by Dr Mikuta in 1969 and was presented as a rare, aggressive form of cervical cancer.•Adenocarcinoma in situ is the precursor of adenocarcinoma.

Metrics

17 Record Views
1 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Nursing
Logo image